A Trial of HRS-1780 in Participants With Uncontrolled Hypertension or Resistant Hypertension.
Trial statusNot yet recruiting
Trial phasePhase 2, Phase 3
Trial typeInterventional
Biological sexAll
Age18-80
SponsorShandong Suncadia Medicine Co., Ltd.
About this trial
The study is being conducted to evaluate the efficacy and safety of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension. To explore the optimal use of HRS-1780 in participants with uncontrolled hypertension or resistant hypertension。
Eligibility criteria
Qualifiers
Male or female, aged ≥ 18 and < 80 years ；
Mean trough seated SBP ≥ 140 mmHg and < 170 mmHg at both screening and randomization visits.
Meet the criteria for uncontrolled hypertension；
Meet the criteria for resistant hypertension；
Disqualifiers
Mean trough seated DBP ≥ 110 mmHg at randomization.
Have a known secondary cause of hypertension, including but not limited to: renal artery stenosis, coarctation of the aorta, uncontrolled or untreated hyperthyroidism/hypothyroidism, pheochromocytoma, or Cushing's syndrome.
History of adrenal insufficiency at screening.
Presence of severe structural heart disease at screening, including severe valvular heart disease, hypertrophic cardiomyopathy, dilated cardiomyopathy, rheumatic heart disease, or congenital heart disease.
Trial design
Treatments tested in this trial
- HRS-1780 tablet
- HRS-1780 tablet
- HRS-1780 tablet
- HRS-1780 tablet placebo
Treatment groups
914 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov